Lenirit (Hydrocortisone Acetate)

Hydrocortisone acetate penetrates the skin and binds to intracellular glucocorticoid receptors. The drug‑receptor complex alters gene transcription, suppressing the production of inflammatory cytokines and inhibiting immune cell migration, which leads to reduced inflammation and immune response at the site of application.

The appropriate dose of Lenirit is determined by the prescribing healthcare professional based on the severity of the skin condition, the size of the affected area, patient age, and any relevant medical history. Patients should follow the prescriber’s instructions and not adjust the amount or frequency on their own.

Safety data for topical hydrocortisone acetate in pregnancy and lactation are limited. Healthcare providers usually weigh the potential benefits against possible risks. Pregnant or nursing individuals should discuss use with their physician before starting treatment.

To order Lenirit, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lenirit contains hydrocortisone acetate, a low‑ to medium‑potency corticosteroid. Compared with higher‑potency steroids such as clobetasol, it offers a milder anti‑inflammatory effect with a lower risk of skin atrophy, making it suitable for sensitive areas and for short‑term use in mild to moderate conditions.

Store Lenirit at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the container tightly closed and out of reach of children. Do not freeze or expose the product to extreme heat.

Apply a thin layer of Lenirit to clean, dry skin in the affected area, usually 1–2 times daily or as directed by a healthcare professional. Gently rub the product until it is absorbed, and wash hands after application unless the hands are being treated.

Serious risks include skin atrophy, hypopigmentation, secondary infections, and systemic adrenal suppression when used over large areas, under occlusion, or for prolonged periods. Patients should report signs such as thinning skin, unusual bruising, or systemic symptoms like fatigue to their clinician promptly.

Lenirit should be avoided in individuals with known hypersensitivity to hydrocortisone acetate or any excipients, on skin infected with bacterial, viral (e.g., herpes simplex), or fungal organisms unless specifically prescribed, and in patients where systemic corticosteroid exposure is contraindicated.